Esperion Therapeutics (ESPR) said Friday it entered into privately negotiated exchange and subscription agreements with certain holders of $210.1 million of its outstanding 4.00% convertible senior subordinated notes due 2025 who agreed to a combination of $57.5 million of new 5.75% convertible senior subordinated notes maturing in 2030 and around $153.4 million in cash for their notes.
Once the exchange transactions close, expected on Dec. 17, the company said around $54.9 million of the 2025 convertible notes will remain outstanding.
Esperion shares were down over 13% shortly ahead of Friday's opening bell.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。